Abiopharma

Johnson & Johnson - Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson - Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies drivingSjögrens disease

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögrens disease

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

SEALSQ Participates as a Lead Investor in Quobly’s €130 Million Series A Financing Via SEALQuantum.com Fund to Advance the European Sovereign Quantum Infrastructure

TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock

Snail Games 庆祝《方舟》上线 11 周年，持续拓展游戏版图

Snail Games 慶祝《ARK》在推出 11 年後持續擴充